WHO ICTRP trial
A phase II study of Irinotecan plus cisplatin as first-line therapy for advanced…
ChiCTR-TNC-11001549 · Chinese Clinical Trial Registry (ChiCTR) · Not Recruiting
Key facts
| Trial ID | ChiCTR-TNC-11001549 |
|---|---|
| Public title | A phase II study of Irinotecan plus cisplatin as first-line therapy for advanced gastric cancer |
| Scientific title | A phase II study of Irinotecan plus cisplatin as first-line therapy for advanced gastric cancer |
| Primary sponsor | Cancer Institute & Hospital Chinese Academy of Medical Sciences |
| Registry | Chinese Clinical Trial Registry (ChiCTR) |
| Recruitment status | Not Recruiting |
| Study type | Observational study |
| Phase | II (Phase II study) |
| Countries | China |
| Conditions | advanced gastric cancer;C16.902 |
| Interventions | Total:irinotecan, 125 mg/m2 (IV) , day 1; Cisplatin, 60 mg/m 2 (IV), day 2; two weeks as a cycle, up to 6 cycles |
| Registration date | Aug 30, 2011 |
| Target size | Total:40 |
| Registry page | chictr.org.cn |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: